Investors & Media

Committee Composition

  Audit Nominating and Governance Compensation
Mike Cola
Mike Cola

Michael Cola currently serves as president and chief executive officer of Medgenics, Inc. Prior to joining Medgencis, he served as president of specialty pharmaceuticals at Shire plc, a global specialty pharmaceutical company he first joined in 2005 as executive vice-president of global therapeutic business units and portfolio management. Previously, Mr. Cola also served as a growth capital provider and president of the life sciences group for Safeguard Scientifics, Inc., where he served as chairman and chief executive officer of Clarient, Inc., and chairman of Laureate Pharma, Inc. In addition, Mr. Cola has held senior positions in product development and commercialization at AstraMerck and AstraZeneca. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He also serves on the board of directors at Vanda Pharmaceuticals Inc. and Pennsylvania BIO, and serves as chairman for the board of governors of the Boys & Girls Clubs of Philadelphia.

Member of the Audit Committee Chair of the Nominating and Governance Committee  
Steven Paul, MD
Steven Paul, MD

Steven Paul has had a distinguished career in neuroscience, particularly in CNS drug discovery and development. Dr. Paul is the former President of the Lilly Research Laboratories of Eli Lilly and Company and now leads the Helen & Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College. Prior to his appointment at Weill Cornell, Dr. Paul spent 17-years at Eli Lilly, during which time he held several key leadership roles, including Vice President of Neuroscience (CNS) Research and Group Vice President of Discovery Research (all therapeutic areas). In his most recent role, he was responsible for the company's overall research and development efforts - helping to expand Lilly's R&D efforts in oncology and biotechnology - resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Dr. Paul served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service.

Dr. Paul has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored over 500 papers and book chapters. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. He is also currently on the board of directors or is a trustee of several organizations, including the Sigma-Aldrich Corporation, Alnylam Pharmaceuticals, the Allen Institute for Brain Sciences, The Mind Research Network and the Foundation for the NIH. Dr. Paul has also served as a member of the National Institute of General Medical Sciences (NIGMS) Advisory Council and was appointed by the Secretary of the Department of Health and Human Services (HHS) as a member of the advisory committee to the Director of the NIH from 2001-2006. Dr. Paul is currently a member of the National Advisory Mental Health Council, NIMH, and is board certified by the American Board of Psychiatry and Neurology.

Dr. Paul received his B.A. in Biology and Psychology from Tulane University, and his M.S. and M.D. degrees from the Tulane University School of Medicine.

Member of the Audit Committee   Member of the Compensation Committee
Howard H. Pien
Howard H. Pien

Howard Pien has been a chairman of Vanda Pharmaceuticals, a CNS development company, and lead independent director of ViroPharma, Inc., an orphan disease company. Additionally, he currently sits on the board of directors of Immunogen, Inc. and Juno Therapeutics, and is also an advisor to the life sciences practice of Warburg Pincus. He is the former chief executive officer and chairman of Medarex, Inc., where he served for two years prior to the company’s acquisition by Bristol-Myers Squibb Company in 2009. While at Medarex, Mr. Pien shepherded the evolution of the company from a technology platform enterprise to a promising developer of oncology and immunology product candidates. Prior to Medarex, he served as president and chief executive officer of Chiron Corporation from 2003 until its acquisition by Novartis in 2006. Mr. Pien held an 11-year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, most recently serving as president of GlaxoSmithKline International. Earlier in his career, Mr. Pien held roles of increasing responsibility at Abbott Laboratories and at Merck & Co.

Mr. Pien completed his MBA in finance at Carnegie Mellon University and his B.S. in civil engineering from Massachusetts Institute of Technology.

  Member of the Nominating and Governance Committee Chair of the Compensation Committee
James Frates
James Frates

Mr. Frates has served as a member of our board of directors since May 2014. He is the Senior Vice President and Chief Financial Officer of Alkermes plc, having held that position since September 2011. From 2007 to 2011, Mr. Frates served as Senior Vice President and Chief Financial Officer of Alkermes, Inc. From 1998 to 2007, Mr. Frates served as Vice President, Chief Financial Officer and Treasurer of Alkermes, Inc. From 1996 to 1998, he was employed at Robertson, Stephens & Company, most recently as a Vice President in Investment Banking. Prior to that time, he was employed at Morgan Stanley & Co. From 2004 to 2009, Mr. Frates served on the board of directors of GPC Biotech AG, a biotechnology company, and was a national director of the Association of Bioscience Financial Officers from 2004 to 2009. Mr. Frates is also a Trustee of St. Paul’s School. We believe Mr. Frates qualifications to sit on our board of directors include his leadership experience, financial expertise, business judgment and industry knowledge.

Chair of the Audit Committee   Member of the Compensation Committee
= Chair = Member = Independent Director